- Home
- LPCN vs AXDX Comparison
LPCN vs AXDX Comparison
Compare LPCN & AXDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- AXDX
- Stock Information
- Founded
- LPCN 1997
- AXDX 1982
- Country
- LPCN United States
- AXDX United States
- Employees
- LPCN N/A
- AXDX N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- AXDX Biotechnology: Laboratory Analytical Instruments
- Sector
- LPCN Health Care
- AXDX Industrials
- Exchange
- LPCN Nasdaq
- AXDX Nasdaq
- Market Cap
- LPCN 16.1M
- AXDX 13.7M
- IPO Year
- LPCN N/A
- AXDX 1996
- Fundamental
- Price
- LPCN $3.40
- AXDX $0.13
- Analyst Decision
- LPCN Strong Buy
- AXDX
- Analyst Count
- LPCN 1
- AXDX 0
- Target Price
- LPCN $10.00
- AXDX N/A
- AVG Volume (30 Days)
- LPCN 10.5K
- AXDX 425.6K
- Earning Date
- LPCN 05-08-2025
- AXDX 05-16-2025
- Dividend Yield
- LPCN N/A
- AXDX N/A
- EPS Growth
- LPCN N/A
- AXDX N/A
- EPS
- LPCN N/A
- AXDX N/A
- Revenue
- LPCN $3,674,834.00
- AXDX $11,698,000.00
- Revenue This Year
- LPCN N/A
- AXDX $7.25
- Revenue Next Year
- LPCN N/A
- AXDX N/A
- P/E Ratio
- LPCN N/A
- AXDX N/A
- Revenue Growth
- LPCN N/A
- AXDX N/A
- 52 Week Low
- LPCN $2.75
- AXDX $0.12
- 52 Week High
- LPCN $11.79
- AXDX $2.09
- Technical
- Relative Strength Index (RSI)
- LPCN 49.75
- AXDX 14.37
- Support Level
- LPCN $3.12
- AXDX $0.12
- Resistance Level
- LPCN $3.60
- AXDX $0.56
- Average True Range (ATR)
- LPCN 0.23
- AXDX 0.05
- MACD
- LPCN 0.01
- AXDX -0.02
- Stochastic Oscillator
- LPCN 40.12
- AXDX 1.49
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About AXDX Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.